{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/novo-nordisk-nvo/",
 "dataUrl": "https://clearank.com/stock/novo-nordisk-nvo/data.json",
 "title": "Novo Nordisk (NVO) Stock Forecast & Price Target (2026)",
 "description": "Novo Nordisk A/S Sponsored (NVO) stock: Healthcare, Drug Manufacturers - General. $190.3B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Novo Nordisk A/S Sponsored (NVO)",
 "published": "2026-07-26T09:34:47+00:00",
 "modified": "2026-09-11T20:47:01.095+00:00",
 "generated": "2026-09-11T21:03:44.458Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "NVO",
  "name": "Novo Nordisk A/S Sponsored",
  "type": "American Depositary Receipt",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "Denmark",
  "website": "https://www.novonordisk.com"
 },
 "quote": {
  "price": 43.07,
  "previousClose": 44.01,
  "change": -0.94,
  "changePercent": -2.15,
  "open": 43.225,
  "high": 43.49,
  "low": 42.725,
  "volume": 576999,
  "averageVolume": 8035720,
  "marketCap": 190301010465,
  "fiftyTwoWeekHigh": 64.16,
  "fiftyTwoWeekLow": 35.12,
  "marketOpen": false,
  "asOf": "2026-09-11T20:47:00.000Z"
 },
 "statistics": {
  "pe": 10.786764,
  "eps": 4.08,
  "dividendYield": 0.026889585510275166,
  "beta": 0.344,
  "priceToSales": 0.5903418,
  "priceToBook": 5.683101,
  "revenueTtm": 51206753217,
  "grossMargin": 0.7821323004790541,
  "returnOnEquity": 0.59815
 },
 "technicals": {
  "rsi": 35.05,
  "macd": -0.76,
  "sma50": 47.56,
  "sma200": 46.27,
  "rsiSignal": "Bearish",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 55,
  "consensus": "Hold",
  "fairValue": 45.2,
  "analystTarget": 45.2,
  "analystCount": 14,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-11T20:47:00.000Z",
  "priceAtAnalysis": 43.065,
  "volatility": {
   "daily": 2.2,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 42.63,
  "aggressiveEntry": 43.07,
  "stopLoss": 41.23,
  "stopLossPercent": 3.3,
  "targets": [
   43.91,
   44.77,
   46.05
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 30.12,
    "base": 46.05,
    "upside90th": 70.4
   },
   {
    "year": 2028,
    "downside10th": 27.01,
    "base": 49.23,
    "upside90th": 89.74
   },
   {
    "year": 2029,
    "downside10th": 25.23,
    "base": 52.64,
    "upside90th": 109.82
   },
   {
    "year": 2030,
    "downside10th": 24.08,
    "base": 56.29,
    "upside90th": 131.57
   },
   {
    "year": 2031,
    "downside10th": 23.29,
    "base": 60.18,
    "upside90th": 155.51
   },
   {
    "year": 2032,
    "downside10th": 22.75,
    "base": 64.35,
    "upside90th": 182.04
   },
   {
    "year": 2033,
    "downside10th": 22.38,
    "base": 68.8,
    "upside90th": 211.55
   },
   {
    "year": 2034,
    "downside10th": 22.14,
    "base": 73.56,
    "upside90th": 244.44
   },
   {
    "year": 2035,
    "downside10th": 22.01,
    "base": 78.66,
    "upside90th": 281.1
   },
   {
    "year": 2036,
    "downside10th": 21.97,
    "base": 84.1,
    "upside90th": 322
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "NVO Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$43.23",
    "Day Range": "$42.73 to $43.49",
    "Prev Close": "$44.01",
    "Volume": "577.0K",
    "52-Week Range": "$35.12 to $64.16",
    "Market Cap": "$190.30B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-66%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "NVO Financial Performance"
  },
  {
   "id": "analysis",
   "title": "NVO Analysis",
   "text": [
    "Novo Nordisk A/S is currently trading below its 50-day and 200-day moving averages ($47.56 and $46.27), indicating a bearish trend. The Relative Strength Index (RSI) is at 35.05, signaling bearish momentum, and the Moving Average Convergence Divergence (MACD) is negative at -0.757. The stock's price is also below its 20-day exponential moving average, reinforcing the short-term downward pressure. Volume has been significantly below average recently, which could indicate a lack of conviction from either buyers or sellers, but the prevailing trend is downward. Investors should watch for any signs of trend reversal or a break above the key moving averages to signal a potential shift.",
    "Current and next quarter revenue estimates show year-over-year declines of 3.00% and 7.00% respectively, indicating potential headwinds for the company's top line.",
    "The stock is trading below its 50-day and 200-day moving averages ($47.56 and $46.27), with RSI at 35.05, signaling bearish momentum and potential for further price depreciation.",
    "While the overall consensus is 'Hold', recent rating changes show a mix of downgrades to 'Neutral' and 'Hold', alongside some 'Buy' initiations, reflecting divided analyst sentiment.",
    "A 2.00% revenue growth is projected for next year, suggesting a potential stabilization and future recovery, which could drive positive sentiment if realized.",
    "The base case for Novo Nordisk A/S over the next 6-12 months suggests a period of stabilization, with the median analyst price target indicating a modest 5.0% upside to $45.20. However, the current technical setup, with the stock trading below key moving averages and exhibiting bearish momentum, presents near-term headwinds. The projected revenue declines in the current and next quarters are a significant concern that could limit upside potential. Upside catalysts could emerge if the company demonstrates a clear path to renewed growth, potentially through new product launches or successful market penetration, which could shift analyst sentiment and technical indicators. Conversely, continued revenue contraction, increased competition within the healthcare sector, or negative clinical trial results could exacerbate current bearish trends and push the stock below its fair value estimate. The company's dividend provides a baseline return, but significant stock appreciation hinges on a turnaround in its growth trajectory."
   ],
   "lists": {
    "ProTips": [
     "Given the projected revenue declines and bearish technicals, consider waiting for confirmation of a trend reversal or a significant improvement in growth outlook before initiating new positions.",
     "The stock's current position below its 50-day and 200-day moving averages ($47.56 and $46.27) suggests that these levels may act as resistance in the near term.",
     "With a dividend yield of 4.31%, NVO may appeal to income-focused investors, but the recent revenue headwinds warrant a thorough assessment of dividend sustainability."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Projected Revenue Decline",
     "text": "Current and next quarter revenue estimates show year-over-year declines of 3.00% and 7.00% respectively, indicating potential headwinds for the company's top line.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bearish",
     "title": "Bearish Technical Momentum",
     "text": "The stock is trading below its 50-day and 200-day moving averages ($47.56 and $46.27), with RSI at 35.05, signaling bearish momentum and potential for further price depreciation.",
     "source": "Technical Analysis"
    },
    {
     "type": "Neutral",
     "title": "Mixed Analyst Ratings",
     "text": "While the overall consensus is 'Hold', recent rating changes show a mix of downgrades to 'Neutral' and 'Hold', alongside some 'Buy' initiations, reflecting divided analyst sentiment.",
     "source": "Analyst Ratings"
    },
    {
     "type": "Bullish",
     "title": "Potential for Growth Re-acceleration",
     "text": "A 2.00% revenue growth is projected for next year, suggesting a potential stabilization and future recovery, which could drive positive sentiment if realized.",
     "source": "Wall Street Estimates"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Novo Nordisk A/S exhibits a P/E ratio of 10.79, which is significantly lower than the sector average of 31.9, suggesting potential undervaluation or reflecting concerns about future growth. The company's reported revenue growth of 2.1% is below the sector median of 8.1%, and forward estimates indicate a projected revenue decline of 3.00% for the current year. This deceleration in growth, coupled with a lower-than-average Return on Equity (ROE) of 6.9% compared to the sector's 6.9%, warrants careful consideration. Despite the lower valuation multiples, the projected revenue contraction raises questions about the sustainability of its current earnings. The company's fair value estimate of $45.20, derived from analyst price targets, suggests a modest upside from the current price, but this is tempered by the negative revenue outlook. Investors should monitor the company's ability to reignite growth and maintain profitability in a competitive healthcare landscape.",
    "Novo Nordisk A/S's recent revenue estimates project a decline, with the current quarter expected to see a 3.00% year-over-year decrease and the next quarter anticipating a 7.00% drop. For the current year, revenue is projected to decrease by 3.00% compared to the previous year. The negative revenue trajectory suggests potential pressure on profitability. The next year's revenue is forecasted to grow by 2.00%, indicating a potential stabilization but still a slow recovery.",
    "Novo Nordisk A/S faces significant risks including projected revenue declines in the near term, which could impact future earnings and valuation. The stock is currently trading below key technical indicators, signaling bearish momentum and potential for further price depreciation. Additionally, the mixed 'Hold' consensus among analysts suggests a lack of strong conviction regarding the company's immediate growth prospects."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "190.30B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "10.79"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "4.08"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "4.31%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "64.16"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "35.12"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Bearish SMA Cross Bullish Price vs SMA Bearish MACD Bearish Golden Cross in effect with the 50-day SMA ($47.56) above the 200-day SMA ($46.27), price is trading below the 50-day SMA."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "35.05"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-0.76"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "47.56"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "46.27"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.29",
    "Correlation with Nasdaq 100 (QQQ)": "+0.24",
    "Correlation with Bitcoin (BTC)": "+0.41",
    "Correlation with Gold (XAU)": "+0.04"
   }
  },
  {
   "id": "trade-plans",
   "title": "NVO Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (35.1) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$43.91",
    "TARGET 2": "$44.77",
    "TARGET 3": "$46.05",
    "STOP LOSS": "$41.23"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+2.08%",
    "Average Feb return": "-2.88%",
    "Average Mar return": "-1.06%",
    "Average Apr return": "+3.85%",
    "Average May return": "+2.54%",
    "Average Jun return": "+1.90%",
    "Average Jul return": "-3.16%",
    "Average Aug return": "+4.80%",
    "Average Sep return": "-3.62%",
    "Average Oct return": "-1.29%",
    "Average Nov return": "+2.20%",
    "Average Dec return": "+1.59%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.20%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in NVO in September 2016 would be worth about $19,093 today, compared with about $35,030 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in NVO today could grow to about $19,529 by 2036 in the base case, with a bull case near $74,771 and a bear case around $5,101. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "NVO Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $56.29 for NVO by 2030 in the base case, from $43.07 today (1.3x over 4 years). The downside path ends near $24.08. These are outcomes of a Monte Carlo simulation run on NVO's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using NVO's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "NVO simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$30.12",
        "$46.05",
        "$70.40"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$27.01",
        "$49.23",
        "$89.74"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$25.23",
        "$52.64",
        "$110"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$24.08",
        "$56.29",
        "$132"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$23.29",
        "$60.18",
        "$156"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$22.75",
        "$64.35",
        "$182"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$22.38",
        "$68.80",
        "$212"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$22.14",
        "$73.56",
        "$244"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$22.01",
        "$78.66",
        "$281"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$21.97",
        "$84.10",
        "$322"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "LLY Eli Lilly and Company NYSE $1,122.31 -0.0619%",
     "url": "https://clearank.com/stock/eli-lilly-lly/"
    },
    {
     "text": "WST West Pharmaceutical Services Inc. NYSE $344.25 +2.17%",
     "url": "https://clearank.com/stock/wst-stock-analysis/"
    },
    {
     "text": "RXRX Recursion Pharmaceuticals, Inc. NASDAQ $3.20 +1.11%",
     "url": "https://clearank.com/stock/rxrx-stock-analysis/"
    },
    {
     "text": "GEHC GE HealthCare Technologies Inc. NASDAQ $64.81 -0.5601%",
     "url": "https://clearank.com/stock/ge-healthcare-gehc/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $880.86 -1.21%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "ABBV AbbVie Inc. NYSE $255.00 +1.63%",
     "url": "https://clearank.com/stock/abbvie-abbv/"
    },
    {
     "text": "FBRX Forte Biosciences, Inc. NASDAQ $76.99 +0.00%",
     "url": "https://clearank.com/stock/fbrx-stock-analysis/"
    },
    {
     "text": "QDEL QuidelOrtho Corporation NASDAQ $12.15 -3.88%",
     "url": "https://clearank.com/stock/quidelortho-qdel/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "BSX vs MDT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/bsx-vs-mdt/"
    },
    {
     "text": "GLD vs IAUM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gld-vs-iaum/"
    },
    {
     "text": "CARR vs TT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/carr-vs-tt/"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Novo Nordisk's stock price forecast for 2030?",
   "answer": "Novo Nordisk's stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $56.29, with a downside scenario of $24.08 and an upside scenario of $131.57. These figures represent statistical outcomes, not guaranteed price targets."
  },
  {
   "question": "Is Novo Nordisk stock a buy right now?",
   "answer": "Novo Nordisk stock is currently rated a 'Hold' by Wall Street analysts, with a consensus score of 55 out of 100. The stock is trading below its key moving averages and shows bearish momentum, suggesting caution."
  },
  {
   "question": "What are the biggest risks for Novo Nordisk?",
   "answer": "The primary risks for Novo Nordisk include projected revenue declines in the upcoming quarters, bearish technical momentum indicated by its position below key moving averages, and a mixed analyst consensus that lacks strong conviction."
  },
  {
   "question": "How does Novo Nordisk's valuation compare to its sector?",
   "answer": "Novo Nordisk's P/E ratio of 10.79 is substantially lower than the healthcare sector average of 31.9, indicating it may be undervalued. However, its revenue growth and ROE are also below sector medians."
  },
  {
   "question": "What is Novo Nordisk's dividend yield?",
   "answer": "Novo Nordisk A/S offers a dividend yield of approximately 4.31%, with a dividend rate of $1.85."
  },
  {
   "question": "What is the outlook for Novo Nordisk's revenue growth?",
   "answer": "Recent estimates project a revenue decline for Novo Nordisk in the current and next quarters, with a 3.00% decrease expected for the current year. A modest 2.00% growth is anticipated for the next year."
  },
  {
   "question": "What are the recent analyst rating changes for Novo Nordisk?",
   "answer": "Recent analyst rating changes include downgrades to 'Neutral' from 'Buy' by Goldman Sachs and JP Morgan in early 2026, and a 'Hold' rating from 'Buy' by Argus Research. However, some analysts initiated 'Outperform' or 'Buy' ratings."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "LLY",
    "name": "Eli Lilly and Company NYSE",
    "price": "$1,122.31",
    "change": "-0.0619%",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "WST",
    "name": "West Pharmaceutical Services Inc. NYSE",
    "price": "$344.25",
    "change": "+2.17%",
    "url": "https://clearank.com/stock/wst-stock-analysis/"
   },
   {
    "ticker": "RXRX",
    "name": "Recursion Pharmaceuticals, Inc. NASDAQ",
    "price": "$3.20",
    "change": "+1.11%",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "name": "GE HealthCare Technologies Inc. NASDAQ",
    "price": "$64.81",
    "change": "-0.5601%",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$880.86",
    "change": "-1.21%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "ABBV",
    "name": "AbbVie Inc. NYSE",
    "price": "$255.00",
    "change": "+1.63%",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   },
   {
    "ticker": "FBRX",
    "name": "Forte Biosciences, Inc. NASDAQ",
    "price": "$76.99",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   },
   {
    "ticker": "QDEL",
    "name": "QuidelOrtho Corporation NASDAQ",
    "price": "$12.15",
    "change": "-3.88%",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   }
  ],
  "comparisons": [
   {
    "ticker": "BSX vs MDT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/bsx-vs-mdt/"
   },
   {
    "ticker": "GLD vs IAUM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gld-vs-iaum/"
   },
   {
    "ticker": "CARR vs TT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/carr-vs-tt/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "DEO",
    "text": "Diageo plc Sponsored",
    "url": "https://clearank.com/stock/deo-stock-analysis/"
   },
   {
    "ticker": "KMB",
    "text": "Kimberly-Clark Corporation",
    "url": "https://clearank.com/stock/kmb-stock-analysis/"
   },
   {
    "ticker": "IAUM",
    "text": "iShares Gold Trust Micro",
    "url": "https://clearank.com/etf/iaum-etf-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "THETA/USD",
    "text": "↑ 15.25%",
    "url": "https://clearank.com/crypto/theta-network-theta-usd/"
   },
   {
    "ticker": "HPE",
    "text": "↑ 10.41%",
    "url": "https://clearank.com/stock/hewlett-packard-enterprise-hpe/"
   },
   {
    "ticker": "DELL",
    "text": "↑ 10.23%",
    "url": "https://clearank.com/stock/dell-technologies-dell/"
   },
   {
    "ticker": "IMSR",
    "text": "↓ 9.79%",
    "url": "https://clearank.com/stock/terrestrial-energy-imsr/"
   },
   {
    "ticker": "SWKS",
    "text": "↑ 9.79%",
    "url": "https://clearank.com/stock/skyworks-solutions-swks/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "LLY",
    "text": "Eli Lilly",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "MRK",
    "text": "Merck",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "PFE",
    "text": "Pfizer",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/NVO-novo-nordisk-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/NVO-novo-nordisk-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Novo Nordisk (NVO) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/novo-nordisk-nvo/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/novo-nordisk-nvo/",
        "name": "Novo Nordisk (NVO) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/novo-nordisk-nvo/#webpage",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/",
     "name": "Novo Nordisk (NVO) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-26T09:34:47+00:00",
     "dateModified": "2026-09-11T20:47:01+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/NVO-novo-nordisk-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/novo-nordisk-nvo/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Novo Nordisk (NVO) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-26T09:34:47+00:00",
     "dateModified": "2026-09-11T20:47:01+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Novo Nordisk A/S Sponsored (NVO) stock: Healthcare, Drug Manufacturers - General. $190.3B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Novo Nordisk (NVO) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/novo-nordisk-nvo/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/novo-nordisk-nvo/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/NVO-novo-nordisk-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/novo-nordisk-nvo/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Novo Nordisk A/S Sponsored (NVO)",
   "tickerSymbol": "NVO",
   "url": "https://clearank.com/stock/novo-nordisk-nvo/",
   "description": "AI-powered financial analysis for Novo Nordisk A/S Sponsored (NVO) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NYSE",
   "offers": {
    "@type": "Offer",
    "price": 43.065,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Novo Nordisk's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Novo Nordisk's stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $56.29, with a downside scenario of $24.08 and an upside scenario of $131.57. These figures represent statistical outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is Novo Nordisk stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Novo Nordisk stock is currently rated a 'Hold' by Wall Street analysts, with a consensus score of 55 out of 100. The stock is trading below its key moving averages and shows bearish momentum, suggesting caution."
     }
    },
    {
     "@type": "Question",
     "name": "What are the biggest risks for Novo Nordisk?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for Novo Nordisk include projected revenue declines in the upcoming quarters, bearish technical momentum indicated by its position below key moving averages, and a mixed analyst consensus that lacks strong conviction."
     }
    },
    {
     "@type": "Question",
     "name": "How does Novo Nordisk's valuation compare to its sector?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Novo Nordisk's P/E ratio of 10.79 is substantially lower than the healthcare sector average of 31.9, indicating it may be undervalued. However, its revenue growth and ROE are also below sector medians."
     }
    },
    {
     "@type": "Question",
     "name": "What is Novo Nordisk's dividend yield?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Novo Nordisk A/S offers a dividend yield of approximately 4.31%, with a dividend rate of $1.85."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for Novo Nordisk's revenue growth?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Recent estimates project a revenue decline for Novo Nordisk in the current and next quarters, with a 3.00% decrease expected for the current year. A modest 2.00% growth is anticipated for the next year."
     }
    },
    {
     "@type": "Question",
     "name": "What are the recent analyst rating changes for Novo Nordisk?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Recent analyst rating changes include downgrades to 'Neutral' from 'Buy' by Goldman Sachs and JP Morgan in early 2026, and a 'Hold' rating from 'Buy' by Argus Research. However, some analysts initiated 'Outperform' or 'Buy' ratings."
     }
    }
   ]
  }
 ]
}